Aarey Drugs & Pharmaceuticals logo

Aarey Drugs & Pharmaceuticals

AAREYDRUGS NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹273 Cr
Volatility
Moderate
P/E Ratio
67.27
EBITDA
₹7.17 Cr
Return on Equity
2.91%
Debt to Equity
0.33
Book Value
₹53.9
52W High
₹101.29
52W Low
₹50.31

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Promoter holding has increased by 5.08% over last quarter.

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 6.27% over past five years.
  • Company has a low return on equity of 3.13% over last 3 years.
  • Earnings include an other income of Rs.6.26 Cr.
  • Promoter holding has decreased over last 3 years: -7.25%

Growth Rate

Revenue Growth
-2.38% lower than 3Y
Net Income Growth
-4.5% lower than 3Y
Cash Flow Change
444% lower than 3Y
ROE
-17.56% lower than 3Y
ROCE
7.03% higher than 3Y
EBITDA Margin (Avg.)
-42.97% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
50.96
57.83
76.48
210
127
105
134
108
102
84.16
96.43
189
44.63
Expenses
49.62
55.99
73.78
212
126
101
132
112
101
81.52
97.94
185
43.31
Operating Profit
1.34
1.84
2.7
-1.44
1.18
3.72
2.2
-4.21
1.71
2.64
-1.51
4.34
1.32
OPM %
2.63%
3.18%
3.53%
-0.68%
0.93%
3.54%
1.64%
-3.89%
1.67%
3.14%
-1.57%
2.29%
2.96%
Other Income
0.7
0.84
0.29
5.14
1.58
0.02
0.68
7.54
1.55
0.79
4.18
-0.43
1.72
Interest
0.42
0.41
0.47
0.4
0.96
0.49
0.58
1.3
1.04
1.26
0.92
1.78
1.67
Depreciation
0.89
1.27
1.06
1.15
0.47
1.51
0.9
0.41
0.49
0.69
0.83
0.85
0.85
PBT
0.73
1
1.46
2.15
1.33
1.74
1.4
1.62
1.73
1.48
0.92
1.28
0.52
Tax %
0%
-22%
30.14%
-0.47%
6.77%
8.62%
48.57%
71.6%
20.81%
31.08%
38.04%
-21.88%
-98.08%
Net Profit
0.72
1.23
1.02
2.15
1.24
1.6
0.72
0.47
1.37
1.02
0.57
1.56
1.02
EPS in Rs
0.28
0.48
0.4
0.77
0.44
0.57
0.25
0.17
0.48
0.36
0.2
0.55
0.36
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
213
246
396
349
354
298
348
493
419
396
474
472
415
Expenses
212
245
386
342
347
294
344
481
411
391
471
465
408
Operating Profit
1
1
10
8
8
3
5
11
8
4
3
7
7
OPM %
0.6%
0.4%
2.4%
2.2%
2.2%
1.1%
1.3%
2.3%
1.8%
1.1%
0.6%
1.5%
1.6%
Other Income
3
3
3
3
4
7
7
3
3
7
10
6
6
Interest
1
2
4
2
2
2
2
2
3
4
5
5
6
Depreciation
1
1
1
1
1
1
1
2
2
2
2
3
3
PBT
1
2
8
8
9
7
8
10
6
5
6
5
4
Tax %
23%
29%
31%
25%
27%
20%
21%
35%
37%
12%
34%
27%
—
Net Profit
1
1
5
6
7
6
7
7
4
5
4
4
4
EPS in Rs
0.65
0.77
3.02
2.64
2.8
2.48
2.78
2.58
1.49
1.67
1.42
1.4
1.47
Div. Payout %
0%
0%
0%
0%
4%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
17
17
18
23
23
23
23
25
25
28
28
28
Reserves
19
20
31
57
63
69
75
88
92
105
110
122
Borrowings
11
15
10
3
16
18
18
14
38
31
35
50
Other Liabilities
69
74
83
86
43
84
116
117
136
139
117
97
Total Liabilities
115
125
142
170
146
194
233
245
291
303
291
297
Fixed Assets
6
8
12
12
12
12
14
14
14
13
16
26
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
2
2
Other Assets
109
117
130
157
133
181
218
230
277
289
272
269
Total Assets
115
125
142
170
146
194
233
245
291
303
291
297
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
3
6
1
-20
1
3
5
0
-1
-3
10
10
Investing
-2
-3
-5
-1
-1
-1
-3
-3
0
-2
-6
-12
Financing
-2
-2
4
23
-2
-2
-2
2
1
6
-4
2
Net Cash Flow
-1
1
-1
2
-3
0
0
0
1
1
0
0
Free Cash Flow
1
3
-4
-21
-1
2
3
-2
-2
-4
5
-2
CFO/OP
239
560
28
-232
37
135
154
36
13
-37
421
164
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
114
108
75
100
109
118
170
101
165
170
103
100
Inventory Days
7
3
5
16
23
21
20
11
26
33
36
33
Days Payable
117
108
71
84
40
98
120
86
115
123
81
66
Cash Conversion Cycle
5
3
9
32
92
42
69
26
76
80
58
68
Working Capital Days
49
40
34
69
77
99
91
68
89
106
89
90
ROCE %
7%
7%
22%
14%
12%
8%
9%
10%
6%
6%
6%
6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aarey Drugs & Pharmaceuticals insights

59 extracted metrics + investor summaries across FY10–FY26.

Log in — free

Shareholding Pattern

DIIs1.62%Public41.66%FIIs4.80%Others14.20%Promot.37.71%As ofJun 2026

Documents

Frequently Asked Questions about Aarey Drugs & Pharmaceuticals

What does Aarey Drugs & Pharmaceuticals Ltd do?
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications[1]
Where is Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) listed?
Aarey Drugs & Pharmaceuticals Ltd trades as AAREYDRUGS on the NSE and under code 524412 on the BSE.
Which sector does Aarey Drugs & Pharmaceuticals Ltd belong to?
Aarey Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹272.54 Cr, which places it in the Small Cap band.
What is the PE ratio of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd trades at a PE ratio of 67.27, against a book value of ₹53.9 per share.
What is the 52-week high and low of Aarey Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Aarey Drugs & Pharmaceuticals Ltd has traded between ₹50.31 and ₹101.29.
What is the Return on Equity (ROE) of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd reported a return on equity of 2.91%. Its debt-to-equity ratio is 0.33.

Company Information

Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications[1]

Website aareydrugs.com
CEO Mr. Mihir Rajesh Ghatalia B.E
Listed 2021-08-06
Face Value ₹ 10
Issued Size 2,83,54,303

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AAREYDRUGS.md for Aarey Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List